Literature DB >> 21263091

Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report.

Elsa Curtit1, Antoine Thiery-Vuillemin, Thierry Nguyen, Bruno Heyd, Xavier Pivot, Vincent Di Martino, Christophe Borg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21263091     DOI： 10.1200/JCO.2010.32.6785

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  21 in total

Review 1.  Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies.

Authors:  Yasunobu Matsuda; Takafumi Ichida; Manabu Fukumoto
Journal:  Med Mol Morphol       Date:  2011-09-16       Impact factor: 2.309

2.  Comment on "combination treatment including targeted therapy for advanced hepatocellular carcinoma".

Authors:  Lijun Zhang; Guangming Li
Journal:  Hepatobiliary Surg Nutr       Date:  2016-10       Impact factor: 7.293

3.  Sustained remission over 36 months of advanced hepatocellular carcinoma after short-term sorafenib therapy.

Authors:  Sun Young Ahn; Hyun Seok Lee; Young Oh Kweon; Won Young Tak; Soo Young Park
Journal:  Dig Dis Sci       Date:  2013-01-10       Impact factor: 3.199

4.  Complete remission of advanced hepatocellular carcinoma by radiofrequency ablation after sorafenib therapy.

Authors:  Jung Gil Park; Soo Young Park; Hye Won Lee
Journal:  World J Gastroenterol       Date:  2015-02-28       Impact factor: 5.742

5.  Sudden cardiac death in a patient with advanced hepatocellular carcinoma with good response to sorafenib treatment: A case report with literature analysis.

Authors:  Linda Calistri; Cesare Cordopatri; Cosimo Nardi; Elena Gianni; Fabio Marra; Stefano Colagrande
Journal:  Mol Clin Oncol       Date:  2017-01-16

6.  Recurrence-free survival of a hepatocellular carcinoma patient with tumor thrombosis of the inferior vena cava after treatment with sorafenib and hepatic resection.

Authors:  Kenichi Nakamura; Toru Beppu; Hiromitsu Hayashi; Hirohisa Okabe; Kastunori Imai; Hidetoshi Nitta; Akira Chikamoto; Takatoshi Ishiko; Masato Sasaki; Hideo Baba
Journal:  Int Surg       Date:  2015-05

7.  Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations.

Authors:  Xiao-Dong Zhu; Cheng Huang; Ying-Hao Shen; Yuan Ji; Ning-Ling Ge; Xu-Dong Qu; Lingli Chen; Wen-Kai Shi; Mei-Ling Li; Jin-Jin Zhu; Chang-Jun Tan; Zhao-You Tang; Jian Zhou; Jia Fan; Hui-Chuan Sun
Journal:  Liver Cancer       Date:  2021-03-30       Impact factor: 11.740

8.  Impact of surgical treatment after sorafenib therapy for advanced hepatocellular carcinoma.

Authors:  Hideaki Takeyama; Toru Beppu; Takaaki Higashi; Takayoshi Kaida; Kota Arima; Katsunobu Taki; Katsunori Imai; Hidetoshi Nitta; Hiromitsu Hayashi; Shigeki Nakagawa; Hirohisa Okabe; Daisuke Hashimoto; Akira Chikamoto; Takatoshi Ishiko; Motohiko Tanaka; Yutaka Sasaki; Hideo Baba
Journal:  Surg Today       Date:  2017-11-07       Impact factor: 2.549

9.  Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection.

Authors:  Toshihiro Kitajima; Etsuro Hatano; Yusuke Mitsunori; Kojiro Taura; Yasuhiro Fujimoto; Masaki Mizumoto; Hideaki Okajima; Toshimi Kaido; Sachiko Minamiguchi; Shinji Uemoto
Journal:  Clin J Gastroenterol       Date:  2015-08-07

10.  Deteriorated portal flow may cause liver failure in patients with hepatocellular carcinoma being treated with sorafenib.

Authors:  Akihiro Yamasaki; Narihiro Umeno; Shigeru Harada; Kosuke Tanaka; Masaki Kato; Kazuhiro Kotoh
Journal:  J Gastrointest Oncol       Date:  2016-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.